Literature DB >> 10216831

Comparison of azacyclic urea A-98881 as HIV-1 protease inhibitor with cage dimeric N-benzyl 4-(4-methoxyphenyl)-1,4-dihydropyridine as representative of a novel class of HIV-1 protease inhibitors: a molecular modeling study.

A Hilgeroth1, R Fleischer, M Wiese, F W Heinemann.   

Abstract

The functional groups of cage dimeric N-alkyl substituted 3,5-bis(hydroxymethyl)-4-(4-methoxyphenyl)-1,4-dihydropyridines are similar to those of cyclic and azacyclic ureas that are potent inhibitors of HIV-1 protease of the dihydroxyethylene- and hydroxyethylene type, respectively. In the following study the conformity of common functional groups is investigated concerning their orientation in space as well as in the enzyme HIV-1 protease. Starting from X-ray crystal data of the centrosymmetric cage dimeric N-benzyl derivative with ester groups, the derivative with hydroxymethylene groups was built and a systematic conformational search was performed for the conformationally important torsion angles considering electrostatic and van der Waals interactions. From the huge number of conformations those comprising centrosymmetrical and C2-symmetrical energy minima were selected and minimized. The three remaining conformers were fitted to the azacyclic urea A-98881 selected from the HIV-1 protease enzyme-inhibitor complex using the centroids of the corresponding aromatic residues and additionally by the field fit option of the Advanced CoMFA module of SYBYL. Interestingly, the energetically most favourable one, which, additionally, possesses C2-symmetry like the active site cavity of HIV-1 protease, showed the best fit. Comparing the electrostatic potential (EP) of the latter with the EP of A-98881 the aromatic residues show excellent accordance. Slight differences in the extent of the EP were found in the areas of the hydroxymethylene groups of the cage dimer and the single hydroxy group as well as the urea carbonyl group of A-98881, respectively. In order to compare the binding possibilities to the enzyme HIV-1 protease for the cage dimer and A-98881, their interaction fields with certain probes (CH3 for alkyl, NHamide, and carbonyl, O- of COO-), representing the decisive functional groups of the active site, have been calculated using GRID and projected into the enzyme placing the structures according to the position of A-98881 in the enzyme-inhibitor complex. The strongest calculated fields of the O- probe were found near Asp 25 for both structures. Another respective conformity consists in the overlap of the fields for the NHamide probe near Ile 50 and 50' for the investigated cage dimer and A-98881.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10216831     DOI: 10.1023/a:1008038608460

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  8 in total

Review 1.  [HIV-1 protease inhibitors in review].

Authors:  A Hilgeroth
Journal:  Pharm Unserer Zeit       Date:  1998-01

Review 2.  Retroviral proteases: structure, function and inhibition from a non-anticipated viral enzyme to the target of a most promising HIV therapy.

Authors:  K von der Helm
Journal:  Biol Chem       Date:  1996-12       Impact factor: 3.915

3.  Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease.

Authors:  A Wlodawer; M Miller; M Jaskólski; B K Sathyanarayana; E Baldwin; I T Weber; L M Selk; L Clawson; J Schneider; S B Kent
Journal:  Science       Date:  1989-08-11       Impact factor: 47.728

4.  A computational procedure for determining energetically favorable binding sites on biologically important macromolecules.

Authors:  P J Goodford
Journal:  J Med Chem       Date:  1985-07       Impact factor: 7.446

5.  Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A.

Authors:  S Seelmeier; H Schmidt; V Turk; K von der Helm
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

6.  Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450.

Authors:  C N Hodge; P E Aldrich; L T Bacheler; C H Chang; C J Eyermann; S Garber; M Grubb; D A Jackson; P K Jadhav; B Korant; P Y Lam; M B Maurin; J L Meek; M J Otto; M M Rayner; C Reid; T R Sharpe; L Shum; D L Winslow; S Erickson-Viitanen
Journal:  Chem Biol       Date:  1996-04

7.  Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS).

Authors:  R C Gallo; P S Sarin; E P Gelmann; M Robert-Guroff; E Richardson; V S Kalyanaraman; D Mann; G D Sidhu; R E Stahl; S Zolla-Pazner; J Leibowitch; M Popovic
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

8.  A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease.

Authors:  H L Sham; C Zhao; K D Stewart; D A Betebenner; S Lin; C H Park; X P Kong; W Rosenbrook; T Herrin; D Madigan; S Vasavanonda; N Lyons; A Molla; A Saldivar; K C Marsh; E McDonald; N E Wideburg; J F Denissen; T Robins; D J Kempf; J J Plattner; D W Norbeck
Journal:  J Med Chem       Date:  1996-01-19       Impact factor: 7.446

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.